S. Iivanainen

发表

Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients

J. Koivunen, C. Jacob, O. Schmalz, 2020, Journal of medical Internet research.

Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study

J. Koivunen, S. Iivanainen, M. Arffman, 2020, ESMO Open.

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study

J. Koivunen, S. Iivanainen, Saara Kuusisalo, 2022, Cancers.

38P Predicting objective response rate (ORR) in immune checkpoint inhibitor (ICI) therapies with machine learning (ML) by combining clinical and patient-reported data

V. Kataja, J. Koivunen, Jussi Ekström, 2020, Annals of Oncology.

Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers

J. Koivunen, S. Iivanainen, Antti Tikkanen, 2020, Journal of Cancer Research and Clinical Oncology.

Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients

J. Koivunen, S. Iivanainen, 2018, Oncology.

Assessment of chemotherapy‐induced neurotoxicity using a point‐of‐care nerve conduction study device

J. Koivunen, S. Iivanainen, Anna Jokimäki, 2022, Cancer reports.

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors

J. Koivunen, S. Iivanainen, A. Knuuttila, 2019, ESMO Open.

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection

J. Koivunen, S. Iivanainen, 2020, International journal of molecular sciences.

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

J. Koivunen, Jussi Ekström, T. Alanko, 2019, Journal of Cancer Research and Clinical Oncology.

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

J. Koivunen, M. D. de Jonge, M. Karvonen, 2021, Annals of Oncology.

Concurrent Metformin Use and Survival Among Finnish Non-Small Cell Lung Cancer Patients Treated With EGFR TKIs

J. Koivunen, S. Iivanainen, M. Arffman, 2021 .

Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study

J. Koivunen, S. Iivanainen, M. Arffman, 2021, Acta oncologica.

Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies

Jussi Ekstrom, Henri Virtanen, Sanna Iivanainen, 2021, BMC Medical Informatics and Decision Making.

Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study

J. Koivunen, P. Vihinen, T. Alanko, 2020, JMIR formative research.

Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients (Preprint)

J. Koivunen, C. Jacob, O. Schmalz, 2020 .

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

P. Jaakkola, M. Karvonen, S. Iivanainen, 2023, medRxiv.

Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study (Preprint)

J. Koivunen, P. Vihinen, T. Alanko, 2020 .

The prognostic and predictive roles of plasma C‐reactive protein and PD‐L1 in non‐small cell lung cancer

J. Koivunen, S. Iivanainen, A. Knuuttila, 2023, Cancer medicine.

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

E. Ruppin, A. Cortellini, D. Pinato, 2023, Journal for ImmunoTherapy of Cancer.

Predicting Onset and Continuity of Patient-Reported Symptoms in Patients Receiving Immune Checkpoint Inhibitor (ICI) Therapies Using Machine Learning

J. Koivunen, Jussi Ekström, S. Iivanainen, 2020, Archives of Clinical and Medical Case Reports.

ePRO symptom follow-up of colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy is feasible and enhances the quality of patient care: a prospective multicenter study

V. Kataja, J. Koivunen, Jussi Ekström, 2023, Journal of Cancer Research and Clinical Oncology.

Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data

V. Kataja, J. Koivunen, Jussi Ekström, 2022, Applied Sciences.

A national precision cancer medicine implementation initiative for Finland

Okko-Sakari Kääriäinen, S. Iivanainen, E. Alanne, 2024, Acta oncologica.